Company / Cost of Revenue
Ultragenyx Pharmaceutical Inc. Cost of Revenue History
FY2017-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$1.1M
FY2018
5-year range
-
FY2017-FY2018
Trend
+114500.0%
vs FY2017
Sector context
#79 of 85
Health Care
What the data says
Among 85 Health Care companies, Ultragenyx Pharmaceutical Inc. is in the top 7% for cost of revenue.
Based on SEC 10-K filings.
$1M in FY2018.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 85This company $1.1M Sector average $2.0B
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2018, cost of revenue increased 114500.0% year-over-year.
- Ranks #79 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $1.1M | +114500.0% |
| FY2017 | $1.0K | - |
| FY2016 | - | - |
As of FY2018 · SEC 10-K · Updated Jun 30, 2026